| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
2,250,000,000 |
| Market
Cap: |
100.91(B) |
| Last
Volume: |
21,280,549 |
Avg
Vol: |
11,944,728 |
| 52
Week Range: |
$44.7 - $69.08 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 100 |
|
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 11.3 |
| Insider 3/6 Months : 11.9 |
|
| Guru Rank Number : 97 |
| Guru Rank Value : 8.6 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
13,571 |
13,571 |
13,571 |
| Total Buy Value |
$0 |
$672,994 |
$672,994 |
$672,994 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
3 |
3 |
3 |
| Total Shares Sold |
0 |
0 |
69,103 |
681,397 |
| Total Sell Value |
$0 |
$0 |
$4,525,215 |
$49,727,684 |
| Total People Sold |
0 |
0 |
3 |
6 |
| Total Sell Transactions |
0 |
0 |
3 |
12 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hirawat Samit |
EVP,Chief Med.Offr.,Drug Dev. |
• – – |
2021-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,356 |
16,538 |
|
- |
|
| Haller Julia A |
Director |
– • – |
2021-06-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
902 |
10,670 |
|
- |
|
| Bonney Michael W |
Director |
– • – |
2021-06-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
902 |
12,501 |
|
- |
|
| Bonney Michael W |
Director |
– • – |
2021-06-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,949 |
11,599 |
|
- |
|
| Eid Joseph |
SVP,Head Glob. Medical Affairs |
• – – |
2021-06-03 |
4 |
D |
$64.80 |
$47,822 |
D/D |
(738) |
9,485 |
|
- |
|
| Eid Joseph |
SVP,Head Glob. Medical Affairs |
• – – |
2021-06-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,154 |
10,223 |
|
- |
|
| Haller Julia A |
Director |
– • – |
2021-06-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,949 |
9,768 |
|
- |
|
| Schmukler Louis S |
EVP,Pres.,Glob.Prod. & Supply |
• – – |
2021-05-10 |
4 |
S |
$65.25 |
$978,750 |
D/D |
(15,000) |
31,956 |
|
5% |
|
| Eid Joseph |
SVP,Head Glob. Medical Affairs |
• – – |
2021-05-10 |
4 |
S |
$65.00 |
$72,670 |
D/D |
(1,118) |
8,069 |
|
5% |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2021-05-08 |
4 |
D |
$64.44 |
$515,133 |
D/D |
(7,994) |
54,390 |
|
- |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2021-05-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,245 |
62,384 |
|
- |
|
| Dubow Adam |
SVP,ChiefCompliance&EthicsOff. |
• – – |
2021-05-05 |
4 |
S |
$64.21 |
$200,271 |
D/D |
(3,119) |
16,243 |
|
4% |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2021-05-05 |
4 |
S |
$64.29 |
$1,963,802 |
D/D |
(30,546) |
45,139 |
|
4% |
|
| Mily Elizabeth |
EVP, Strategy & BD |
• – – |
2021-04-01 |
4 |
D |
$62.93 |
$185,769 |
D/D |
(2,952) |
4,241 |
|
- |
|
| Mily Elizabeth |
EVP, Strategy & BD |
• – – |
2021-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,346 |
5,380 |
|
- |
|
| Mily Elizabeth |
EVP, Strategy & BD |
• – – |
2021-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
847 |
4,509 |
|
- |
|
| Caforio Giovanni |
Chairman and CEO |
• • – |
2021-03-22 |
4 |
AS |
$62.20 |
$1,555,000 |
D/D |
(25,000) |
528,980 |
|
7% |
|
| Schmukler Louis S |
EVP,Pres.,Glob.Prod. & Supply |
• – – |
2021-03-10 |
4 |
D |
$60.93 |
$888,908 |
D/D |
(14,589) |
46,956 |
|
- |
|
| Schmukler Louis S |
EVP,Pres.,Glob.Prod. & Supply |
• – – |
2021-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
3,450 |
55,516 |
|
- |
|
| Schmukler Louis S |
EVP,Pres.,Glob.Prod. & Supply |
• – – |
2021-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,575 |
53,018 |
|
- |
|
| Schmukler Louis S |
EVP,Pres.,Glob.Prod. & Supply |
• – – |
2021-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(257) |
31,471 |
|
- |
|
| Von Autenried Paul |
EVP, Chief Information Officer |
• – – |
2021-03-10 |
4 |
D |
$60.93 |
$610,336 |
D/D |
(10,017) |
139,670 |
|
- |
|
| Von Autenried Paul |
EVP, Chief Information Officer |
• – – |
2021-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
2,854 |
146,039 |
|
- |
|
| Von Autenried Paul |
EVP, Chief Information Officer |
• – – |
2021-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,302 |
143,800 |
|
- |
|
| Von Autenried Paul |
EVP, Chief Information Officer |
• – – |
2021-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(167) |
129,952 |
|
- |
|
2225 Records found
|
|
Page 9 of 89 |
|
|
0.15 (0.34%) 
